RenewVax raises €3.6M Seed round
18 October 2024· Liverpool, United Kingdom· health, biotech, ai, b2b, deep_hardware
The funding is intended for the development of pneumococcal vaccines designed to prevent life-threatening bacterial infections and building a Streptococcus pyogenes vaccine.
Investors
LeadSFC Capital
Also participating
Innovate UKUniversity of LiverpoolUniversity of Liverpool Endowment
About RenewVax
Stage
Seed
Headquarters
Liverpool, United Kingdom
Founded
2022
Team Size
6–20
Sectors
healthbiotechaib2bdeep_hardware